Dinesh Saralaya - Concepedia

Author

Dinesh Saralaya

Bradford Teaching Hospitals NHS Foundation Trust ORCID

Also Known As

A Sanderson, A. Sanderson, AERATOR group, Alexandra Ross, D Saralaya, D. Saralaya, DINESH SARALAYA, Dinesh Saralaya, E McIvor, E. Sapey

101

Publications

4.5K

Citations

H-Index

Concepts

All Affiliations

Bradford Teaching Hospitals NHS Foundation Trust University Hospital Southampton NHS Foundation Trust University of Oxford University College London University of Nottingham

About

Dinesh Saralaya is an author at Bradford Teaching Hospitals NHS Foundation Trust specializing in medicine, immunology, and covid-19.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	11	1.7K
2	Allergy	3	3	478
3	Allergy Medicine	3	3	478
4	Epidemiology	1	1	10
5	Hospital Medicine	1	1	555

Dinesh Saralaya

Publications

3.2K

Citations

H-Index

Page 1

	Year	Citations
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Eugenia Abaleke, Mustafa Abbas, Sadia Abbasi, The Lancet Long CovidAntimicrobial StewardshipAntibioticsClinical InfectionPlatform Trial	2021	555
Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial Phillip Monk, Richard Marsden, Victoria Tear, The Lancet Respiratory Medicine Sars-cov-2 InfectionCovid-19 PandemicImmunologyAntiviral TherapyRespiratory Infection	2020	448
Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study Rachael A Evans, Olivia C. Leavy, Matthew Richardson, The Lancet Respiratory Medicine	2022	407
Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial William W. Busse, Eugene R. Bleecker, J Mark FitzGerald, The Lancet Respiratory Medicine AsthmaRheumatologyExtension TrialAllergyAllergy Medicine	2018	298
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Obbina Abani, Ali Abbas, Fatima Abbas, The Lancet	2021	289
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial Alasdair Munro, Shuo Feng, Leila Janani, The Lancet Infectious Diseases	2022	170
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial Tim Harrison, Pascal Chanez, Francesco Menzella, The Lancet Respiratory Medicine AsthmaSevere Eosinophilic AsthmaAllergyInflammatory Lung DiseaseAllergy Medicine	2020	168
The Inhalation Characteristics of Patients When They Use Different Dry Powder Inhalers Wahida Azouz, Philip Chetcuti, Harold Hosker, Journal of Aerosol Medicine and Pulmonary Drug Delivery	2014	103
Time course of changes in driving simulator performance with and without treatment in patients with sleep apnoea hypopnoea syndrome. Peter M Turkington, Monica Sircar, Dinesh Saralaya, PubMed	2004	95
Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial Paul T. Heath, Eva Galiza, D. N. Baxter, Clinical Infectious Diseases	2022	72

Page 1